EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on
Healthcare Conference
TARRYTOWN, N.Y., Nov. 28 -- EpiCept Corporation (Nasdaq and OMX Nordic
Exchange: EPCT) today announced that Jack Talley, President and CEO, will
present a company overview at the BMO Capital Markets Focus on Healthcare
Conference on December 5, 2007 at 11:00 a.m. Eastern Time. The conference will
be held at The Millennium Broadway Hotel in New York City on December 4th and
5th. Mr. Talley will present a company overview.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )
The presentation will be available live via webcast on December 5, 2007. The
webcast can be accessed by visiting the Company's website at www.epicept.com. A
replay of the presentation will be available following the event.
About EpiCept Corporation
EpiCept is focused on unmet needs in the treatment of pain and cancer. The
Company has a staged portfolio of pharmaceutical product candidates with several
pain therapies in late-stage clinical trials, and a lead oncology compound (for
acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial;
a marketing authorization application for this compound has been submitted in
Europe. EpiCept is based in Tarrytown, N.Y., and its research and development
team in San Diego is pursuing a drug discovery program focused on novel
approaches to apoptosis.
Forward-Looking Statements
This news release and any oral statements made with respect to the information
contained in this news release, contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include statements which express plans, anticipation,
intent, contingency, goals, targets, future development and are otherwise not
statements of historical fact. These statements are based on EpiCept's current
expectations and are subject to risks and uncertainties that could cause actual
results or developments to be materially different from historical results or
from any future results expressed or implied by such forward-looking statements.
Factors that may cause actual results or developments to differ materially
include: the risk that Ceplene will not receive regulatory approval or marketing
authorization in the EU or that Ceplene, if approved, will not achieve
significant commercial success, the risk that Myriad's development of Azixa(TM)*
will not be successful, the risk that Azixa will not receive regulatory approval
or achieve significant commercial success, the risk that EpiCept will not
receive any significant payments under its agreement with Myriad, the risk that
the development of the Company's other apoptosis product candidates will not be
successful, the risk that its ASAP technology will not yield any successful
product candidates, the risk that clinical trials for NP-1 or EPC 2407 will not
be successful, that NP-1 or EPC 2407 will not receive regulatory approval or
achieve significant commercial success, the risk that the Company's other
product candidates that appeared promising in early research and clinical trials
do not demonstrate safety and/or efficacy in larger-scale or later stage
clinical trials, the risk that EpiCept will not obtain approval to market any of
its product candidates, the risks associated with reliance on additional outside
financing to meet its capital requirements, the risks associated with dependence
upon key personnel, the risks associated with reliance on collaborative partners
and others for further clinical trials, development, manufacturing and
commercialization of its product candidates; the cost, delays and uncertainties
associated with its scientific research, product development, clinical trials
and regulatory approval process; its history of operating losses since
inception; competition; litigation; risks associated with prior material
weaknesses in internal controls; and risks associated with the Company's ability
to protect its intellectual property. These factors and other material risks are
more fully discussed in EpiCept's periodic reports, including its reports on
Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange
Commission. You are urged to carefully review and consider the disclosures found
in EpiCept's filings which are available at www.sec.gov or at www.epicept.com.
You are cautioned not to place undue reliance on any forward-looking statements,
any of which could turn out to be wrong due to inaccurate assumptions, unknown
risks or uncertainties or other risk factors.
EPCT-GEN
*Azixa is a registered trademark of Myriad Genetics, Inc.
SOURCE EpiCept Corporation
-0- 11/28/2007
/CONTACT: Robert W. Cook, EpiCept Corporation, +1-914-606-3500,
rcook@epicept.com; Investors, Kim Sutton Golodetz, +1-212-838-3777,
kgolodetz@lhai.com or Bruce Voss, +1-310-691-7100, bvoss@lhai.com, both of
Lippert/Heilshorn & Associates; or Media, Greg Kelley, Feinstein Kean
Healthcare, +1-617-577-8110, gregory.kelley@fkhealth.com /
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com /
/Web site: http://www.epicept.com /
(EPCT)
EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
| Source: Immune Pharmaceuticals Inc